Literature DB >> 20079934

Obesity and smoking in patients with schizophrenia and normal controls: a case-control study.

Konstantinos N Fountoulakis1, Melina Siamouli, Panagiotis Panagiotidis, Stamatia Magiria, Sotiris Kantartzis, Natalia Papastergiou, George Shoretsanitis, Eleonora Pantoula, Katerina Moutou, Evangelia Kouidi, Symeon Deres.   

Abstract

Cardiovascular risk factors, especially obesity and smoking are highly prevalent in patients with schizophrenia. Central obesity and the metabolic syndrome are conditions mostly attributed to the use of antipsychotic medication and lifestyle habits, and they constitute a significant health concern. Our study sample included 105 patients suffering from schizophrenia aged 36.25+/-10.03 and 156 normal control subjects aged 36.03+/-11.33. All patients were in- or out-patients of a private hospital. Clinical diagnosis was made according to DSM-IV-TR criteria. Height, weight, waist circumference and number of cigarettes smoked daily were recorded. Duration of illness was calculated based on records concerning the age of first onset of psychotic symptoms. Body Surface Area (BSA) and Body Mass Index (BMI) were calculated as well as % body fat, with the use of LifeWise Body Fat Analyzers No 63-1525. The results of analysis of variance suggested a significant main effect regarding diagnosis and sex as well as for their interaction. There were significant differences between patients and controls regarding body weight, waist circumference, BMI, BSA and % body fat, with patients, especially females, being more obese than controls. The results of the present study corroborate the increased prevalence of obesity in schizophrenia. The interpretation of this finding remains unclear. Copyright 2008 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20079934     DOI: 10.1016/j.psychres.2008.11.018

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Add-on exercise interventions for smoking cessation in people with mental illness: a systematic review and meta-analysis.

Authors:  Stefanie E Schöttl; Martin Niedermeier; Prisca Kopp-Wilfling; Anika Frühauf; Carina S Bichler; Monika Edlinger; Bernhard Holzner; Martin Kopp
Journal:  BMC Sports Sci Med Rehabil       Date:  2022-06-21

2.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

3.  Relative Risk of Acute Myocardial Infarction in People with Schizophrenia and Bipolar Disorder: A Population-Based Cohort Study.

Authors:  Shu-I Wu; Su-Chiu Chen; Shen-Ing Liu; Fang-Ju Sun; Jimmy J M Juang; Hsin-Chien Lee; Kai-Liang Kao; Michael E Dewey; Martin Prince; Robert Stewart
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

4.  Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.

Authors:  Georgios Schoretsanitis; Céline Dubath; Claire Grosu; Marianna Piras; Nermine Laaboub; Setareh Ranjbar; Nicolas Ansermot; Séverine Crettol; Frederik Vandenberghe; Franziska Gamma; Armin von Gunten; Kerstin Jessica Plessen; Erich Seifritz; Philippe Conus; Chin B Eap
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-02-17       Impact factor: 3.688

5.  Dietary Intake in Body Mass Index Differences in Community-Based Japanese Patients with Schizophrenia.

Authors:  Haruyuki Ito; Takako Kumagai; Midori Kimura; Shotaro Koike; Takeshi Shimizu
Journal:  Iran J Public Health       Date:  2015-05       Impact factor: 1.429

6.  Dietary patterns are associated with obesity in Japanese patients with schizophrenia.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Yasushi Sato; Manabu Saito; Hanako Furukori; Taku Nakagami; Masamichi Ishioka; Sunao Kaneko
Journal:  BMC Psychiatry       Date:  2014-06-20       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.